ATE202709T1 - Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten - Google Patents

Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten

Info

Publication number
ATE202709T1
ATE202709T1 AT95100661T AT95100661T ATE202709T1 AT E202709 T1 ATE202709 T1 AT E202709T1 AT 95100661 T AT95100661 T AT 95100661T AT 95100661 T AT95100661 T AT 95100661T AT E202709 T1 ATE202709 T1 AT E202709T1
Authority
AT
Austria
Prior art keywords
csf
binding protein
pharmaceutically acceptable
tnf binding
acceptable salt
Prior art date
Application number
AT95100661T
Other languages
English (en)
Inventor
Gottfried Alber
Peter Angehrn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE202709T1 publication Critical patent/ATE202709T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95100661T 1994-02-04 1995-01-19 Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten ATE202709T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810059 1994-02-04

Publications (1)

Publication Number Publication Date
ATE202709T1 true ATE202709T1 (de) 2001-07-15

Family

ID=8218199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95100661T ATE202709T1 (de) 1994-02-04 1995-01-19 Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten

Country Status (16)

Country Link
US (2) US5776895A (de)
EP (1) EP0668077B1 (de)
JP (1) JP2765807B2 (de)
CN (1) CN1097468C (de)
AT (1) ATE202709T1 (de)
AU (1) AU693833B2 (de)
BR (1) BR9500436A (de)
CA (1) CA2139385C (de)
DE (1) DE69521536T2 (de)
DK (1) DK0668077T3 (de)
ES (1) ES2160643T3 (de)
GR (1) GR3036774T3 (de)
NZ (1) NZ270422A (de)
PT (1) PT668077E (de)
RU (1) RU2139084C1 (de)
ZA (1) ZA95679B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6419919B2 (en) * 1997-11-07 2002-07-16 John D. Mountz Method for the augmentation of gene expression
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
AU766826B2 (en) * 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
ES2370235T3 (es) * 2001-02-23 2011-12-13 Immunex Corporation Recuperación eficaz de proteínas replegadas correctamente.
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
WO2003076567A2 (en) * 2002-03-05 2003-09-18 Eli Lilly And Company Heterologous g-csf fusion proteins
RU2207373C1 (ru) * 2002-04-25 2003-06-27 ООО "Новэнерго" Способ получения человеческого гранулоцитарного колониестимулирующего фактора
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
BRPI0407649A (pt) 2003-02-28 2006-02-21 Ares Trading Sa formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
NZ580530A (en) * 2007-06-06 2012-04-27 Domantis Ltd Anti vegf polypeptides, antibody variable domains and antagonists
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
MX2011000859A (es) 2008-07-23 2011-02-24 Ambrx Inc Polipeptidos g-csf bovinos modificados y sus usos.
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
JP7179464B2 (ja) 2015-01-20 2022-11-29 アイジーエム バイオサイエンシズ インコーポレイテッド 腫瘍壊死因子 （ｔｎｆ） スーパーファミリー受容体結合分子およびその使用
MX2020003742A (es) * 2017-10-11 2020-10-28 Elanco Us Inc Variantes del factor estimulador de colonias de granulocitos de porcino y sus usos.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1018552B1 (de) * 1985-08-23 2006-07-05 Kirin-Amgen, Inc. Produktion des pluripotenten Granulozyten-Koloniestimulierungsfaktors
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4985241A (en) * 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US5021551A (en) * 1989-01-18 1991-06-04 Washington University Method of enhancing peptide immunogenicity
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
DE59010908D1 (de) * 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
AU1235692A (en) * 1991-01-18 1992-08-27 Synergen, Inc. Methods for treating tumor necrosis factor mediated diseases
WO1993011793A1 (en) * 1991-12-17 1993-06-24 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
EP0639079B1 (de) * 1992-04-30 2000-01-12 Amgen Inc. Methoden zur Behandlung von Interleukin- 1 und - Tumor - Nekrose - Faktor - verursachten Krankheiten
DK0642356T3 (da) * 1992-05-05 2003-08-04 Aeres Biomedical Ltd Antistoffer mod P-selectin og deres anvendelser

Also Published As

Publication number Publication date
BR9500436A (pt) 1995-10-17
JP2765807B2 (ja) 1998-06-18
GR3036774T3 (en) 2002-01-31
CN1097468C (zh) 2003-01-01
JPH07258300A (ja) 1995-10-09
US5776895A (en) 1998-07-07
CN1111158A (zh) 1995-11-08
US5750503A (en) 1998-05-12
CA2139385A1 (en) 1995-08-05
PT668077E (pt) 2001-12-28
AU693833B2 (en) 1998-07-09
DE69521536T2 (de) 2002-04-18
RU2139084C1 (ru) 1999-10-10
AU1146295A (en) 1995-08-17
DE69521536D1 (de) 2001-08-09
ZA95679B (en) 1995-08-08
ES2160643T3 (es) 2001-11-16
RU95101385A (ru) 1996-12-27
NZ270422A (en) 1996-06-25
DK0668077T3 (da) 2001-10-08
CA2139385C (en) 2001-12-25
EP0668077B1 (de) 2001-07-04
EP0668077A1 (de) 1995-08-23

Similar Documents

Publication Publication Date Title
DE69521536D1 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
BG101118A (en) Therapeutical compounds
CA2148194A1 (en) Cyclopeptides of the formula i
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
EP0347899A3 (en) Pharmaceutical compositions on egg shell basis and their preparation and use
EP0281070A3 (de) Pharmazeutische Zusammensetzung für die Krebsbehandlung
EP0410749A3 (en) Anthocyanidins for the treatment of ophthalmic diseases
MY104521A (en) Treatment of depression.
IL102032A0 (en) 2-amino-5-cyano-1,4-dihydropyridines,their preparation and pharmaceutical compositions containing them
IL91152A0 (en) Furylthiazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
EP0384302A3 (de) Verwendung von Ubenimex zur Hestellung eines Medikaments zur Behandlung des myelodysplastischen Syndroms
CA2097878A1 (en) Therapeutic agent for neutropenia
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
HUT60145A (en) Process for producing pharmaceutical composition comprising human interleukin-2 and suitable for treating pneumothorax

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification